Finance

GSK hails a major breakthrough with one of its cancer treatments, boosting shares by 0.9%


GSK hails a major breakthrough with one of its cancer treatments, boosting shares by 0.9%

Glaxosmithkline has hailed a major breakthrough with one of its cancer treatments

Glaxosmithkline has hailed a major breakthrough with one of its cancer treatments

Glaxosmithkline has hailed a major breakthrough with one of its cancer treatments.

The British drugs firm reported positive results from a final-stage trial of Zejula, one of the most promising medicines being developed by its subsidiary Tesaro. 

It said the daily pill improved survival rates among women who had previously had chemotherapy for ovarian cancer.

Zejula is a type of drug known as a ‘PARP inhibitor’, which aim to stop cancer cells in a tumour from repairing themselves, causing them to die.

Hal Barron, president of research and development, described the results as ‘exciting’ as shares went up 0.9 per cent, or 14.8p, to 1638.6p. 

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close